Cellectar Biosciences, Inc. — Director's Dealing 2017

Nov 16, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2017-11-14

Reporting Person: NEIS JOHN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-14	Common Stock, par value $0.00001 per share	S	5214	$1.4942	Disposed	626103	Indirect

Footnotes

F1: Advantage Capital Wisconsin Partners I, Limited Partnership sold 5,214 shares which represented all of its Cellectar holdings in order for the fund to make its final distributions and dissolve before the end of 2017.

F2: The price reported in Column 4 of Line 1 with respect to the 5,214 shares sold on November 14, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnote (2) to this Form 4.

F3: These securities are held by Advantage Capital Wisconsin Partners I, Limited Partnership. Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of Venture Investors LLC are made collectively by five managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein.